Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: A cross-sectional study

Ravi Retnakaran, Byung Soo Youn, Ying Liu, Anthony J G Hanley, Nam Seok Lee, Ji Woo Park, Eun Sun Song, Vivian Vu, Wi Kim, Rungsunn Tungtrongchitr, Peter J Havel, Michael M. Swarbrick, Collin Shaw, Gary Sweeney

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Objective: Here we use a novel ELISA that is specific for full-length visfatin (PBEF/NAMPT), compare it with the existing C-terminal based assay and use it to investigate associations of visfatin with metabolic parameters. Design, patients and measurements: We established the specificity and effectiveness of the new ELISA and evaluated the associations of full-length visfatin with clinical, anthropometric and metabolic parameters in a cross-sectional study of 129 Thai subjects, consisting of 50 outpatients with type 2 diabetes and 79 healthy volunteers. Results: The new ELISA accurately recovered full-length recombinant visfatin and detected visfatin secreted by primary human and rat adipocytes. We found serum full-length visfatin was significantly higher in subjects with diabetes compared to their nondiabetic peers (median 2.75 vs. 2.22 ng/ml, P = 0.0142). After adjustment for age, gender and traditional metabolic risk factors, adjusted mean visfatin remained significantly higher in the diabetes group (3.80 vs. 2.10 ng/ml, P = 0.0021). On Spearman univariate correlation analysis, visfatin was significantly associated with resistin (r = 0.30, P = 0.0011), but not with any other anthropometric or metabolic variables, including adiponectin multimers. On multiple linear regression analysis, the only covariates independently associated with visfatin were diabetes (t = 3.11, P = 0.0024) and log resistin (t = 2.68, P = 0.0086). Conclusions: Circulating visfatin is independently associated with diabetes and resistin concentration, but is not related to adiponectin multimers or other metabolic covariates. These data are suggestive of a potential role of visfatin in subclinical inflammatory states.

Original languageEnglish (US)
Pages (from-to)885-893
Number of pages9
JournalClinical Endocrinology
Volume69
Issue number6
DOIs
StatePublished - Dec 2008

Fingerprint

Nicotinamide Phosphoribosyltransferase
Cross-Sectional Studies
Resistin
Enzyme-Linked Immunosorbent Assay
Adiponectin
Adipocytes
Type 2 Diabetes Mellitus
Linear Models
Healthy Volunteers

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes : A cross-sectional study. / Retnakaran, Ravi; Youn, Byung Soo; Liu, Ying; Hanley, Anthony J G; Lee, Nam Seok; Park, Ji Woo; Song, Eun Sun; Vu, Vivian; Kim, Wi; Tungtrongchitr, Rungsunn; Havel, Peter J; Swarbrick, Michael M.; Shaw, Collin; Sweeney, Gary.

In: Clinical Endocrinology, Vol. 69, No. 6, 12.2008, p. 885-893.

Research output: Contribution to journalArticle

Retnakaran, R, Youn, BS, Liu, Y, Hanley, AJG, Lee, NS, Park, JW, Song, ES, Vu, V, Kim, W, Tungtrongchitr, R, Havel, PJ, Swarbrick, MM, Shaw, C & Sweeney, G 2008, 'Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: A cross-sectional study', Clinical Endocrinology, vol. 69, no. 6, pp. 885-893. https://doi.org/10.1111/j.1365-2265.2008.03264.x
Retnakaran, Ravi ; Youn, Byung Soo ; Liu, Ying ; Hanley, Anthony J G ; Lee, Nam Seok ; Park, Ji Woo ; Song, Eun Sun ; Vu, Vivian ; Kim, Wi ; Tungtrongchitr, Rungsunn ; Havel, Peter J ; Swarbrick, Michael M. ; Shaw, Collin ; Sweeney, Gary. / Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes : A cross-sectional study. In: Clinical Endocrinology. 2008 ; Vol. 69, No. 6. pp. 885-893.
@article{d8c0379ce5f94ac8be379b565763cf08,
title = "Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: A cross-sectional study",
abstract = "Objective: Here we use a novel ELISA that is specific for full-length visfatin (PBEF/NAMPT), compare it with the existing C-terminal based assay and use it to investigate associations of visfatin with metabolic parameters. Design, patients and measurements: We established the specificity and effectiveness of the new ELISA and evaluated the associations of full-length visfatin with clinical, anthropometric and metabolic parameters in a cross-sectional study of 129 Thai subjects, consisting of 50 outpatients with type 2 diabetes and 79 healthy volunteers. Results: The new ELISA accurately recovered full-length recombinant visfatin and detected visfatin secreted by primary human and rat adipocytes. We found serum full-length visfatin was significantly higher in subjects with diabetes compared to their nondiabetic peers (median 2.75 vs. 2.22 ng/ml, P = 0.0142). After adjustment for age, gender and traditional metabolic risk factors, adjusted mean visfatin remained significantly higher in the diabetes group (3.80 vs. 2.10 ng/ml, P = 0.0021). On Spearman univariate correlation analysis, visfatin was significantly associated with resistin (r = 0.30, P = 0.0011), but not with any other anthropometric or metabolic variables, including adiponectin multimers. On multiple linear regression analysis, the only covariates independently associated with visfatin were diabetes (t = 3.11, P = 0.0024) and log resistin (t = 2.68, P = 0.0086). Conclusions: Circulating visfatin is independently associated with diabetes and resistin concentration, but is not related to adiponectin multimers or other metabolic covariates. These data are suggestive of a potential role of visfatin in subclinical inflammatory states.",
author = "Ravi Retnakaran and Youn, {Byung Soo} and Ying Liu and Hanley, {Anthony J G} and Lee, {Nam Seok} and Park, {Ji Woo} and Song, {Eun Sun} and Vivian Vu and Wi Kim and Rungsunn Tungtrongchitr and Havel, {Peter J} and Swarbrick, {Michael M.} and Collin Shaw and Gary Sweeney",
year = "2008",
month = "12",
doi = "10.1111/j.1365-2265.2008.03264.x",
language = "English (US)",
volume = "69",
pages = "885--893",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes

T2 - A cross-sectional study

AU - Retnakaran, Ravi

AU - Youn, Byung Soo

AU - Liu, Ying

AU - Hanley, Anthony J G

AU - Lee, Nam Seok

AU - Park, Ji Woo

AU - Song, Eun Sun

AU - Vu, Vivian

AU - Kim, Wi

AU - Tungtrongchitr, Rungsunn

AU - Havel, Peter J

AU - Swarbrick, Michael M.

AU - Shaw, Collin

AU - Sweeney, Gary

PY - 2008/12

Y1 - 2008/12

N2 - Objective: Here we use a novel ELISA that is specific for full-length visfatin (PBEF/NAMPT), compare it with the existing C-terminal based assay and use it to investigate associations of visfatin with metabolic parameters. Design, patients and measurements: We established the specificity and effectiveness of the new ELISA and evaluated the associations of full-length visfatin with clinical, anthropometric and metabolic parameters in a cross-sectional study of 129 Thai subjects, consisting of 50 outpatients with type 2 diabetes and 79 healthy volunteers. Results: The new ELISA accurately recovered full-length recombinant visfatin and detected visfatin secreted by primary human and rat adipocytes. We found serum full-length visfatin was significantly higher in subjects with diabetes compared to their nondiabetic peers (median 2.75 vs. 2.22 ng/ml, P = 0.0142). After adjustment for age, gender and traditional metabolic risk factors, adjusted mean visfatin remained significantly higher in the diabetes group (3.80 vs. 2.10 ng/ml, P = 0.0021). On Spearman univariate correlation analysis, visfatin was significantly associated with resistin (r = 0.30, P = 0.0011), but not with any other anthropometric or metabolic variables, including adiponectin multimers. On multiple linear regression analysis, the only covariates independently associated with visfatin were diabetes (t = 3.11, P = 0.0024) and log resistin (t = 2.68, P = 0.0086). Conclusions: Circulating visfatin is independently associated with diabetes and resistin concentration, but is not related to adiponectin multimers or other metabolic covariates. These data are suggestive of a potential role of visfatin in subclinical inflammatory states.

AB - Objective: Here we use a novel ELISA that is specific for full-length visfatin (PBEF/NAMPT), compare it with the existing C-terminal based assay and use it to investigate associations of visfatin with metabolic parameters. Design, patients and measurements: We established the specificity and effectiveness of the new ELISA and evaluated the associations of full-length visfatin with clinical, anthropometric and metabolic parameters in a cross-sectional study of 129 Thai subjects, consisting of 50 outpatients with type 2 diabetes and 79 healthy volunteers. Results: The new ELISA accurately recovered full-length recombinant visfatin and detected visfatin secreted by primary human and rat adipocytes. We found serum full-length visfatin was significantly higher in subjects with diabetes compared to their nondiabetic peers (median 2.75 vs. 2.22 ng/ml, P = 0.0142). After adjustment for age, gender and traditional metabolic risk factors, adjusted mean visfatin remained significantly higher in the diabetes group (3.80 vs. 2.10 ng/ml, P = 0.0021). On Spearman univariate correlation analysis, visfatin was significantly associated with resistin (r = 0.30, P = 0.0011), but not with any other anthropometric or metabolic variables, including adiponectin multimers. On multiple linear regression analysis, the only covariates independently associated with visfatin were diabetes (t = 3.11, P = 0.0024) and log resistin (t = 2.68, P = 0.0086). Conclusions: Circulating visfatin is independently associated with diabetes and resistin concentration, but is not related to adiponectin multimers or other metabolic covariates. These data are suggestive of a potential role of visfatin in subclinical inflammatory states.

UR - http://www.scopus.com/inward/record.url?scp=55949117816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949117816&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2008.03264.x

DO - 10.1111/j.1365-2265.2008.03264.x

M3 - Article

C2 - 18410550

AN - SCOPUS:55949117816

VL - 69

SP - 885

EP - 893

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 6

ER -